The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects

Diabetologia. 1980 Aug;19(2):93-6. doi: 10.1007/BF00421851.

Abstract

Gastric acid secretion and gastrointestinal hormone levels were measured in healthy non-diabetic subjects after metformin treatment (1.5 g/day). The maximum acid output was increased from 15.7 +/- 3.9 mmol/h (mean +/- SEM) to 30.0 +/- 7.1 mmol/h (p < 0.05) and the peak acid output was increased from 16.4 +/- 4.1 mmol/h to 31.7 +/- 7.2 mmol/h (p < 0.05) after two weeks treatment. Serum insulin, gastric inhibitory polypeptide and secretin levels were normal. After treatment for one week, however, there was a significant increase in fasting vasoactive intestinal peptide (VIP) from 83 +/- 6 ng/1 to 102 +/- 9 ng/1 (p < 0.02) and in stimulated VIP from 58 +/- 5 ng/1 to 79 +/- 5 ng/1 (p < 0.05). Stimulated glucagon-like immunoreactivity (GLI) was also increased from 82 +/- 10 ng/1 to 174 +/- 24 ng/1 (p < 0.01) after one week's treatment. It is suggested that metformin acts as a weak histamine agonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Fasting
  • Gastric Inhibitory Polypeptide / blood
  • Gastric Juice / metabolism*
  • Gastrointestinal Hormones / metabolism*
  • Glucagon / blood
  • Humans
  • Metformin*
  • Vasoactive Intestinal Peptide / blood

Substances

  • Gastrointestinal Hormones
  • Vasoactive Intestinal Peptide
  • Gastric Inhibitory Polypeptide
  • Glucagon
  • Metformin